🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to publish our #YoungMI analysis in JAMA Cardiology this week exploring how socioeconomic disadvantage impacts outcomes post-MI A thread 🧵 With unparalleled mentorship and expert guidance from Ron Blankstein Dr. Deepak L. Bhatt Rishi Wadhera, MD MPP @ersied727 ja.ma/3oIwAHD

Cardiac amyloid is probably more common than we think! AND the inclusion of these pts in HFpEF trials is likely adding to negative results.... Check out the recent article with recent data from Johns Hopkins Cardiology,Virginia Shalkey Hahn, MD and others! CardioNerds BU Amyloidosis Center

COVID Update: There is potentially news out of Israel worth paying attention to. One implication is when it makes sense to boost again in the US. 1/

Frailty and cardiovascular outcomes in the National Health and Aging Trends Study. Read more in EHJ! ow.ly/Tpej50FH9Yd #elderly #frailty #coronary #CVD #outcome #cardiotwitter European Society of Cardiology European Society of Cardiology Journals

Powerful work! And an excellent summation of where we are with frailty & CVD so far!

Proud to announce the publication of CAPITAL DOREMI in NEJM - a comparison of milrinone and dobutamine in cardiogenic shock. Contrary to the hypothesis milrinone was not superior to dobutamine in this randomized double blind comparison. nejm.org/doi/full/10.10…

This one chart is the single most powerful thing to show people in your life.

Added EMPEROR-Preserved, showing the baseline risk and relationship with ARR, now for HFpEF and HFrEF. HFpEF patients have high event rates, but no where near HFrEF patients (in the clinical trials)